CIK 0001534969
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
SERA PROGNOSTICS, INC.
Sign in to watch- Ticker
- SERA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 261911522
- Phone
- +1 801-990-0520
- Business address
- 2749 E. PARLEYS WAY, SUITE 200, SALT LAKE CITY, UT, 84109
- Former names
- SERA PROGNOSTICS, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,563
- in 6 filings
Net −$79,563. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-06 | Boniface John J. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −1,000 | 4,844 | ||
| 2022-04-05 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $3.35 | $9K | 90,110 |
| 2022-03-29 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $3.73 | $10K | 92,835 |
| 2022-03-23 | Jackson Benjamin General Counsel | Grant or award · Stock Option (right to buy) | +60,345 | 60,345 | ||
| 2022-03-23 | CRITCHFIELD GREGORY C Chief Executive Officer | Grant or award · Stock Option (right to buy) | +429,225 | 429,225 | ||
| 2022-03-23 | Altomare Nadia Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +75,735 | 75,735 | ||
| 2022-03-23 | Harrison Robert Gardner Chief Information Officer | Grant or award · Stock Option (right to buy) | +33,698 | 33,698 | ||
| 2022-03-23 | Boniface John J. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +121,705 | 121,705 | ||
| 2022-03-23 | MOYES JAY M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +168,275 | 168,275 | ||
| 2022-03-23 | Kearney Paul Chief Data Officer | Grant or award · Stock Option (right to buy) | +30,426 | 30,426 | ||
| 2022-03-22 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $3.68 | $10K | 95,560 |
| 2022-03-14 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $3.94 | $11K | 98,285 |
| 2022-03-11 | Boniface John J. Chief Scientific Officer | Exercise or conversion | +75,998 | $0.73 | $55K | 101,010 |
| 2022-03-11 | Boniface John J. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −75,998 | 0 | ||
| 2022-01-28 | Foley Michael R Chief Medical Officer | Grant or award · Stock Option (right to buy) | +276,000 | 276,000 | ||
| 2021-12-06 | Boniface John J. Chief Scientific Officer | Exercise or conversion | +25,012 | $0.73 | $18K | 25,012 |
| 2021-12-06 | Boniface John J. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −25,012 | 0 | ||
| 2021-11-29 | Lawrence Sandra AJ Director | Grant or award · Stock Option (right to buy) | +40,332 | 40,332 | ||
| 2021-11-08 | Lindgardt Zhenya Director | Grant or award · Stock Option (right to buy) | +38,325 | 38,325 | ||
| 2021-11-01 | Kearney Paul Chief Data Officer | Grant or award · Stock Option (right to buy) | +107,000 | 107,000 |
Page 20 of 23 · 457 trades